MRI Fat‐Saturated T2‐Weighted Radiomics Model for Identifying the Ki‐67 Index of Soft Tissue Sarcomas

Background Ki‐67 expression has been shown to be an important risk factor associated with prognosis in patients with soft tissue sarcomas (STSs). Its assessment requires fine‐needle biopsy and its accuracy can be influenced by tumor heterogeneity. Purpose To develop and test an MRI‐based radiomics nomogram for identifying the Ki‐67 status of STSs. Study type Retrospective. Population A total of 149 patients at two independent institutions (training cohort [high Ki‐67/low ki‐67]: 102 [52/50], external validation cohort [high Ki‐67/low ki‐67]: 47 [28/19]) with STSs. Field Strength/Sequence Fat‐saturated T2‐weighted imaging (FS‐T2WI) with a fat‐suppressed fast spin/turbo spin echo sequence at 1.5 T or 3 T. Assessment After radiomics feature extraction, logistic regression (LR), random forest (RF), support vector machine (SVM), and k‐nearest neighbor (KNN) were used to construct radiomics models to distinguish between high and low Ki‐67 status. Clinical‐MRI characteristics included age, gender, location, size, margin, and MRI morphological features (size, margin, signal intensity, and peritumoral hyperintensity) were assessed. Univariate and multivariate logistic regression analysis were applied for screening significant risk factors. Radiomics nomogram was constructed by radiomics signature and risk factors. Statistical Tests Model performances (discrimination, calibration, and clinical usefulness) were validated in the validation cohort. The nomogram was assessed using the Harrell index of concordance (C‐index), calibration curve analysis. The clinical utility of the model was assessed by decision curve analysis (DCA). Results LR, RF, SVM, and KNN models represented AUCs of 0.789, 0.755, 0.726, and 0.701 in the validation cohort ( P > 0.05). The nomogram had a C‐index of 0.895 (95% CI: 0.837–0.953) in the training cohort and 0.852 (95% CI: 0.796–0.957) in the validation cohort and it demonstrated good calibration and clinical utility ( P = 0.972 for the training cohort and P = 0.727 for the validation cohort). Data Conclusion This MRI‐based radiomics nomogram developed showed good performance in identifying Ki‐67 expression status in STSs. Level of Evidence 3. Technical Efficacy Stage 2.